Intarcia’s Implantable GLP-1 Gets Unanimous No Vote But Lots Of New Trial Design Advice

 
• By Sarah Karlin-Smith

US FDA advisory panel feels there could be a place for Intarcia’s exenatide drug-device combo – if the company is willing to put in the work.

Diabetes
Intarcia’s last ditch attempt to change FDA’s mind on its diabetes implant looks unlikely after negative advisory panel vote • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers